From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Metabolism Hepatic (mostly via conjugation)[1]
Half-life 12 h[1]
Excretion Renal[1]
CAS number 2622-26-6
ATC code N05AC01
PubChem CID 4747
DrugBank DB01608
ChemSpider 4585
UNII 3405M6FD73 YesY
KEGG D01485 YesY
Chemical data
Formula C21H23N3OS 
Mol. mass 365.49 g/mol
 YesY (what is this?)  (verify)

Periciazine (INN; also known as pericyazine (BAN) or propericiazine) is a medication that belongs to the phenothiazine class of typical antipsychotics. It has also been studied in the treatment of opiate dependence.[2]

Pericyazine is not approved for sale in the United States. It is commonly sold in Canada under the tradename Neuleptil and in United Kingdom and Australia under the tradename Neulactil.[3]

Medical Uses[edit]

The primary uses of pericyazine include in the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia.[1]

Adverse effects[edit]

Pericyazine is a rather sedating and anticholinergic antipsychotic and despite being classed with the typical antipsychotics its risk of extrapyramidal side effects is comparatively low.[4] It has a relatively high risk of causing hyperprolactinaemia and a moderate risk of causing weight gain and orthostatic hypotension.[4]


  1. ^ a b c d "NEULACTIL PRODUCT INFORMATION" (PDF). TGA eBusiness Services. sanofi-aventis australia pty ltd. 13 September 2011. Retrieved 2 November 2013. 
  2. ^ Sivolap IuP, Savchenkov VA (1999). "[The use of neuroleptics in treating opiate dependence]". Zh Nevrol Psikhiatr Im S S Korsakova (in Russian) 99 (6): 29–34. PMID 10441864. 
  3. ^ "Pericyazine". Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 23 September 2011. Retrieved 2 November 2013. 
  4. ^ a b "Approximate relative frequency (not intensity) of common adverse effects of antipsychotics (Table 8.21) [NB1]". eTherapeutic Guidelines complete. Therapeutic Guidelines Limited. February 2013. Retrieved 2 November 2013. 

External links[edit]